摘要
目的评价替罗非班治疗急性缺血性脑卒中(AIS)的安全性及有效性。方法计算机检索PubMed,Embase,The Cochrane Library,Web of Science数据库,检索时间为各数据库自建库起至2022年2月18日。收集替罗非班(试验组)对比常规治疗方案(对照组)治疗AIS的随机对照试验(RCT)文献,按Cochrane系统评价员手册评价文献质量,采用RevMan 5.3统计学软件对治疗的安全性及有效性进行Meta分析。结果共纳入5篇文献,涉及1095例患者。试验组患者颅内出血发生率[OR=1.08,95%CI(0.72,1.62),P=0.72]和症状性出血转化发生率[OR=0.80,95%CI(0.21,3.01),P=0.74]均与对照组相当,但死亡率显著低于对照组[OR=0.46,95%CI(0.24,0.88),P=0.02];试验组患者90 d预后良好率显著高于对照组[OR=1.37,95%CI(1.02,1.85),P=0.03]。结论替罗非班治疗AIS安全性良好,不会升高患者颅内出血及症状性出血转化的发生率,可显著降低死亡率,改善患者的长期预后。
Objective To evaluate the safety and efficacy of tirofiban in the treatment of acute ischemic stroke(AIS).Methods The randomized controlled trial(RCT)of tirofiban(test group)versus the conventional treatment scheme(control group)in the treatment of AIS were searched from the PubMed,Embase,The Cochrane Library and Web of Science databases from the inception of each database to February 18,2022.The quality of the extracted data was evaluated according to the Cochrane system evaluator manual,and the safety and effectiveness of the treatment were analyzed by the RevMan 5.3 statistical software.Results A total of five articles were included,involving 1095 patients.The incidence of intracranial hemorrhage[OR=1.08,95%CI(0.72,1.62),P=0.72]and the conversion rate of symptomatic hemorrhage[OR=0.80,95%CI(0.21,3.01),P=0.74]in the test group were similar to those in the control group,but the death rate[OR=0.46,95%CI(0.24,0.88),P=0.02]was significantly lower than that in the control group.The 90-day good prognosis rate[OR=1.37,95%CI(1.02,1.85),P=0.03]in the test group was significantly higher than that in the control group.Conclusion incidence of intracranial hemorrhage and symptomatic hemorrhage in patients,and can significantly reduce mortality and improve the long-term prognosis of patients.
作者
刘惠莲
王菊
王源江
王埮
LIU Huilian;WANG Ju;WANG Yuanjiang;WANG Tan(Department of Neurology,The First Affiliated Hospital of Hainan Medical College,Haikou,Hainan,China 570102)
出处
《中国药业》
CAS
2023年第4期106-111,共6页
China Pharmaceuticals
基金
海南省高等学校科学研究项目[Hnky2019-49]
海南省临床医学中心建设项目[琼卫医函[2021]276号]。
